Tech entrepreneur Bryan Johnson, known for his high-profile quest to defy aging, announced he was diagnosed with autoimmune gastritis (AIG) in May 2026. Despite years of rigorous health monitoring, the condition-an inflammatory disease affecting the stomach lining-had likely been developing silently for a long time. Johnson credits his intense health regimen for catching the issue before it led to severe complications.
The 48-year-old shared his diagnosis on X (formerly Twitter). Autoimmune gastritis is a chronic illness where the immune system attacks the stomach’s mucosa, often causing a deficiency in vitamin B12 and iron, which may lead to anemia. Management focuses on monitoring nutrient deficits and the stomach’s condition over time. Patients face increased risks of pernicious anemia and precancerous changes.
Johnson attributes his illness partly to lifestyle choices from earlier in life. He recalled growing up eating sugary cereals and soda, frequently indulging in fast food. Later, as a father of three and a business founder, he gained around 18 kilograms amid stress and struggled with chronic depression. He believes these factors could have triggered a cascade of autoimmune attacks, starting with his thyroid before progressing to his stomach.
Bryan Johnson’s autoimmune gastritis diagnosis and longevity journey
Johnson’s health struggles come with a public spotlight. A Silicon Valley figurehead in the longevity scene, he invests millions in anti-aging pursuits, takes dozens of daily supplements, and shares detailed biomarker data like a quarterly earnings report. Netflix documented his efforts in the 2024 film Do Not Die: The Man Who Wants to Live Forever.
He’s no stranger to tech entrepreneurship either. Johnson founded Braintree, the payment platform that acquired Venmo before selling to PayPal for $800 million. More recently, he launched Blueprint, a lifestyle brand selling supplements, olive oil, and other products aimed at healthspan extension.
Johnson presents his autoimmune gastritis diagnosis as proof of his health philosophy. He openly stated that without his rigorous health practices over the past five years, the outcome could have been much worse. He also vowed to explore ”experimental approaches” to treatment and invited researchers working on autoimmune gastritis to connect with him.
Still, many critics remain unconvinced. Johnson’s extreme biohacking experiments-from young blood transfusions involving his son to sharing intimate data like his teenager’s nighttime erections and microplastic content in semen-have drawn ridicule. The medical community is far less enthusiastic than his social media followers. For instance, young donor plasma transfusions have not been proven effective and have raised safety warnings from the U.S. FDA years ago.
Johnson’s autoimmune gastritis diagnosis also highlights the limits of the booming longevity industry. Global spending on longevity products and services has surged into the tens of billions of dollars, growing at double-digit rates, according to Grand View Research. His experience shows that even with access to advanced diagnostics, wearables, and medical experts, some ”incurable” conditions remain out of reach. This raises tough questions about the promises of the biohacking and anti-aging sector.
As Johnson continues his search for novel therapies, his case may spark renewed scrutiny of longevity claims and encourage more rigorous scientific validation. Whether the industry’s outlandish claims can withstand the reality of chronic diseases like autoimmune gastritis will influence how consumers and investors perceive the future of life-extension technology.